Posaconazole
Article Sidebar
Main Article Content
Abstract
Posaconazole is a triazole derivative antifungal agent available in three formulations: oral suspension, delayed-release tablet, and intravenous injection. It was approved by the United States Food and Drug Administration on September 15, 2006; November 25, 2013; and March 14, 2014, respectively. Clinically, posaconazole is used to prophylaxis of invasive fungal infections caused by Aspergillus spp. and Candida spp. in patients aged 13 years and older. It is also prescribed for the treatment of oropharyngeal candidiasis (OPC), including cases refractory to itraconazole and fluconazole. Posaconazole is a potent inhibitor of the enzyme lanosterol 14α-demethylase, which catalyzes a essential step in ergosterol biosynthesis, thereby inhibiting fungal cell growth.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
National Center for Biotechnology Information. PubChem compound summary for CID 468595, posaconazole [Internet]. 2026 [cited 2026 Feb 24]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Posaconazole
U.S. Food and Drug Administration. NOXAFIL® (posaconazole) [Internet]. 2021 [cited 2026 Feb 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214770s000,205053s012,205596s012lbl.pdf
Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimi-crob Agents Chemother 2009;53:958-66.
Lignell A, Löwdin E, Cars O, Chryssanthou E, Sjölin J. Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentra-tion. Antimicrob Agents Chemother 2011;55:3099-104.
Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) 2007;20:188-96.
Lipp HP. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol 2010;70:471-80.
Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, et al. Evaluation of posaconazole pharmacokinetics in adult patients with invasive fungal infection. Biomedicines [Internet]. 2017 [cited 2026 Mar 1];5(4):66. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5744090/pdf/biomedicines-05-00066.pdf
Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Brüggemann RJM. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs 2020;80:671-95.
Drugs and Lactation Database (LactMed®). Posaconazole [Internet]. 2024 [cited 2026 Mar 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK609661/pdf/Bookshelf_NBK609661.pdf
Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Ex-pert Rev Clin Pharmacol 2015;8:321-34.
